10 results about "Serum markers" patented technology

This invention discloses the application of the serum biomarker miR-206 in the preparation of Alzheimer's disease diagnostic products. This invention is the first to use the serum biomarker miR-206 in the effective and auxiliary diagnosis of Alzheimer's disease, demonstrating extremely high diagnostic performance. This invention lays the technical and data foundation for the development of stable and reliable Alzheimer's disease point-of-care testing kits or automated chemiluminescence detection systems and other in vitro diagnostic products. It has significant clinical application prospects in promoting the transformation of early screening and auxiliary diagnosis of Alzheimer's disease from reliance on complex imaging and cerebrospinal fluid examinations to convenient, non-invasive blood tests.

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.

This invention discloses an early ovarian cancer auxiliary diagnostic system based on multimodal fusion, belonging to the field of early ovarian cancer auxiliary diagnostic technology. It includes a data acquisition module, an image feature extraction module, a non-image feature extraction module, a multimodal fusion module, and a diagnostic output module. The data acquisition module acquires raw ultrasound images, serum biomarker test values, and clinical variable data; the image feature extraction module extracts image depth features; the non-image feature extraction module extracts non-image features; the multimodal fusion module dynamically calculates the attention weights of the two modalities and generates fused features; and the diagnostic output module outputs risk probability values. This invention overcomes the limitations of single-modal diagnosis by dynamically and adaptively fusing multimodal data such as ultrasound images, serum biomarkers, and clinical variables, significantly improving the accuracy of early ovarian cancer diagnosis, while also possessing interpretability and clinical deployment feasibility.

The present invention provides liver cancer-associated serum microRNA markers and a new method for diagnosing liver cancer, wherein the liver cancer-associated serum microRNA markers consist of hsa-miR-122, hsa-miR-21, hsa-miR-2115, hsa-miR-221, hsa-miR-27 and hsa-miR-4499; relative expression level of the liver cancer-associated serum microRNA markers in serum is tested using Real-time PCR method, and reagents for the testing contains primers of the liver cancer-associated serum microRNA markers. The present invention can be used to diagnose hepatocellular carcinoma, in particular early hepatocellular carcinoma or to distinguish the serum of at least one patient with hepatocellular carcinoma from the serum of at least one healthy individual, the serum of at least one patient with chronic hepatitis B or the serum of at least one patient with liver cirrhosis.

The present application relates to the technical field of systemic vasculitis identification, in particular to a biomarker for systemic vasculitis diagnosis and application thereof, wherein the biomarker combination comprises the following serum markers: cold-inducible RNA binding protein, myeloid cell trigger receptor-1, Toll-like receptor 4. The biomarker provided by the present application is used for systemic vasculitis diagnosis, disease activity assessment, kidney damage risk early warning and treatment effect monitoring, so as to solve the technical problem of lack of specific and sensitive biomarkers in the prior art.

The application provides a miscarriage risk assessment method and system of whole-exome load and serum markers, comprising: independently scoring each variation in whole-exome sequencing data to obtain a comprehensive pathogenic score; constructing a gene pathogenic load matrix; mapping the gene pathogenic load to a biological pathway to obtain a pathway comprehensive score and construct a model; solving the model by jointly optimizing the regularization strength parameters of the two-layer ridge penalty terms, outputting significant pathway features; standardizing and preprocessing serum detection data; jointly modeling the output significant pathway features and the output standardized serum data under the same logistic regression probability framework, outputting a miscarriage-related risk probability value, and performing probability stratification. The application also outputs a double-track coordination coefficient to quantify the directional consistency of genetic signals and serum signals. It is significantly superior to a single omics solution and provides a high-precision individualized risk assessment tool for recurrent miscarriage with normal karyotype.

The application relates to the technical field of disease diagnosis, and particularly relates to application of CEACAM21 as a serum marker in diagnosis of membranous nephropathy. Based on the marker, risk stratification and treatment decision of the membranous nephropathy can be carried out, and the application has significant clinical significance.

This invention relates to a group of extracellular vesicle-derived biomarkers for gastrointestinal malignancies and their applications, belonging to the field of molecular biology. The biomarkers of this invention are derived from extracellular vesicles and include proteins CALR, SPP1, OLFM4, and OIT3. When used for the diagnosis of gastrointestinal cancers, these biomarkers have shown good diagnostic efficacy, superior to existing serum biomarkers. Furthermore, the biomarkers of this invention show significant elevations in the early stages of gastrointestinal cancer, which is beneficial for early screening and diagnosis of gastrointestinal cancers.

This invention provides a combination of serum biomarkers for the diagnosis of gastric cancer and their applications. This invention is the first to discover that CHI3L1, FCGBP, TFF2, and VSIG2 are significantly elevated in the serum of gastric cancer patients. ROC curve analysis verified that the combination of these four proteins as serum biomarkers can effectively distinguish between gastric cancer patients and healthy controls, and that combined use can better differentiate between early and late-stage gastric cancer patients, demonstrating superior diagnostic value for gastric cancer. Compared with traditional methods for gastric cancer diagnosis, the serum biomarker combination established in this invention is non-invasive, improving the accuracy of gastric cancer diagnosis. It can be used as a health screening test and provides an efficient and non-invasive detection method for gastric cancer patients who cannot undergo pathological examination.